{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T12:54:59Z","timestamp":1792068899901,"version":"4.4.0"},"reference-count":61,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T00:00:00Z","timestamp":1784937600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","oooojournal.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.oooo.2026.07.006","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T15:32:13Z","timestamp":1784820733000},"page":"971-980","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Oral toxicities secondary to targeted therapies in patients with cancer: a large retrospective analysis"],"prefix":"10.1016","volume":"142","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8371-5201","authenticated-orcid":false,"given":"Nivethitha","family":"Nagarajan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Brondfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamal","family":"Al-Eryani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khurrum","family":"Qureshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Villa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.oooo.2026.07.006_bib0001","first-page":"311","article-title":"Targeted therapies: a new generation of cancer treatments","volume":"77","author":"Gerber","year":"2008","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.oooo.2026.07.006_bib0002","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/nature03095","article-title":"Targeted cancer therapy","volume":"432","author":"Sawyers","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.oooo.2026.07.006_bib0003","article-title":"Small molecules in targeted cancer therapy: advances, challenges, and future perspectives","volume":"6","author":"Zhong","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.oooo.2026.07.006_bib0004","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.ejphar.2018.07.034","article-title":"Molecular targeted therapy: treating cancer with specificity","volume":"834","author":"Lee","year":"2018","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.oooo.2026.07.006_bib0005","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1038\/s12276-022-00864-3","article-title":"Molecular targeted therapy for anticancer treatment","volume":"54","author":"Min","year":"2022","journal-title":"Exp Mol Med"},{"key":"10.1016\/j.oooo.2026.07.006_bib0006","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.mpmed.2015.10.012","article-title":"Targeted therapy in cancer","volume":"44","author":"Charlton","year":"2016","journal-title":"Medicine"},{"key":"10.1016\/j.oooo.2026.07.006_bib0007","article-title":"Review: precision medicine and driver mutations: computational methods, functional assays and conformational principles for interpreting cancer drivers","volume":"15","author":"Nussinov","year":"2019","journal-title":"PLoS Comput Biol"},{"key":"10.1016\/j.oooo.2026.07.006_bib0008","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1093\/annonc\/mdv382","article-title":"Targeting the undruggable: immunotherapy meets personalized oncology in the genomic era","volume":"26","author":"Martin","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.oooo.2026.07.006_bib0009","article-title":"Toward a tiered model to share clinical trial data and samples in precision oncology","volume":"5","author":"Broes","year":"2018","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.oooo.2026.07.006_bib0010","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/cas.13505","article-title":"Whole genome sequencing analysis for cancer genomics and precision medicine","volume":"109","author":"Nakagawa","year":"2018","journal-title":"Cancer Sci"},{"key":"10.1016\/j.oooo.2026.07.006_bib0011","article-title":"Targeted RT study: results on early toxicity of targeted therapies and radiotherapy","volume":"19","author":"Konnerth","year":"2024","journal-title":"Rad Onc"},{"key":"10.1016\/j.oooo.2026.07.006_bib0012","first-page":"249","article-title":"Understanding, recognizing, and managing toxicities of targeted anticancer therapies","volume":"63","author":"Dy","year":"2013","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.oooo.2026.07.006_bib0013","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/jhm.12975","article-title":"Clinical progress note: life-threatening side effects of targeted therapies for solid tumors","volume":"18","author":"Thomas","year":"2023","journal-title":"J Hosp Med"},{"key":"10.1016\/j.oooo.2026.07.006_bib0014","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1053\/j.seminoncol.2015.09.032","article-title":"Understanding toxicities of targeted agents: implications for anti-tumor activity and management","volume":"42","author":"Liu","year":"2015","journal-title":"Semin Oncol"},{"key":"10.1016\/j.oooo.2026.07.006_bib0015","doi-asserted-by":"crossref","first-page":"lgz012","DOI":"10.1093\/jncimonographs\/lgz012","article-title":"Oral mucosal injury caused by targeted cancer therapies","volume":"2019","author":"Carrozzo","year":"2019","journal-title":"J Natl Cancer Inst Monogr"},{"key":"10.1016\/j.oooo.2026.07.006_bib0016","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24098188","article-title":"Pathogenesis of oral toxicities associated with targeted therapy and immunotherapy","volume":"24","author":"Villa","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.oooo.2026.07.006_bib0017","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/jop.12135","article-title":"Oral mucosal injury caused by cancer therapies: current management and new frontiers in research","volume":"43","author":"Jensen","year":"2014","journal-title":"J Oral Pathol Med"},{"key":"10.1016\/j.oooo.2026.07.006_bib0018","doi-asserted-by":"crossref","first-page":"4515","DOI":"10.1093\/bioinformatics\/btz409","article-title":"PatientExploreR: an extensible application for dynamic visualization of patient clinical history from electronic health records in the OMOP common data model","volume":"35","author":"Glicksberg","year":"2019","journal-title":"Bioinformatics"},{"key":"10.1016\/j.oooo.2026.07.006_bib0019","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1002\/hed.27646","article-title":"Orofacial complications from immune checkpoint inhibitors: a retrospective analysis from two academic medical centers","volume":"46","author":"Al-Eryani","year":"2024","journal-title":"Head Neck"},{"key":"10.1016\/j.oooo.2026.07.006_bib0020","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1200\/JCO.23.02750","article-title":"Prevention and management of osteoradionecrosis in patients with head and neck cancer treated with radiation therapy: ISOO-MASCC-ASCO guideline","volume":"42","author":"Peterson","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.oooo.2026.07.006_bib0021","first-page":"920","article-title":"American association of oral and maxillofacial surgeons\u2019 position paper on medication-related osteonecrosis of the jaws\u20142022 update","volume":"80","author":"Ruggiero","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.oooo.2026.07.006_bib0022","doi-asserted-by":"crossref","first-page":"E382","DOI":"10.1093\/oncolo\/oyad279","article-title":"Comparisons of non-oral immune-related adverse events among patients with cancer with different oral toxicity profiles","volume":"29","author":"Xu","year":"2024","journal-title":"Oncologist"},{"key":"10.1016\/j.oooo.2026.07.006_bib0023","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.jaad.2018.10.062","article-title":"Inflammatory eruptions associated with immune checkpoint inhibitor therapy: a single-institution retrospective analysis with stratification of reactions by toxicity and implications for management","volume":"80","author":"Coleman","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.oooo.2026.07.006_bib0024","doi-asserted-by":"crossref","first-page":"24","DOI":"10.36401\/JIPO-23-14","article-title":"Oral toxicities associated with immune checkpoint inhibitors: meta-analyses of clinical trials","volume":"7","author":"Srivastava","year":"2024","journal-title":"J Immunother Precis Oncol"},{"key":"10.1016\/j.oooo.2026.07.006_bib0025","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.annder.2022.11.012","article-title":"Oral mucosal toxicities induced by immune checkpoint inhibitors: clinical features and algorithm management","volume":"150","author":"Vigarios","year":"2023","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.oooo.2026.07.006_bib0026","article-title":"MASCC\/ISOO clinical practice statement: management of oral complications of targeted therapy","volume":"32","author":"Villa","year":"2024","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.oooo.2026.07.006_bib0027","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.oooo.2022.11.016","article-title":"Prevalence of acute oral mucosal damage secondary to the use of systemic antineoplastics: a systematic review and meta-analysis","volume":"135","author":"Rodr\u00edguez-Fuentes","year":"2023","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"10.1016\/j.oooo.2026.07.006_bib0028","first-page":"1713","article-title":"Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors","volume":"25","author":"Vigarios","year":"2017","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.oooo.2026.07.006_bib0029","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1634\/theoncologist.2011-0111","article-title":"Oral adverse events associated with tyrosine kinase and mammalian target of rapamycin inhibitors in renal cell carcinoma: a structured literature review","volume":"17","author":"Boers-Doets","year":"2012","journal-title":"Oncologist"},{"key":"10.1016\/j.oooo.2026.07.006_bib0030","first-page":"3243","article-title":"Risk of oral and gastrointestinal mucosal injury among patients receiving selected targeted agents: a meta-analysis","volume":"21","author":"Elting","year":"2013","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.oooo.2026.07.006_bib0031","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.oraloncology.2012.11.008","article-title":"A review of oral toxicity associated with mTOR inhibitor therapy in cancer patients","volume":"49","author":"Martins","year":"2013","journal-title":"Oral Oncol"},{"key":"10.1016\/j.oooo.2026.07.006_bib0032","article-title":"Rituximab safety profile: a seven-year retrospective analysis from Southern India","volume":"16","author":"Jayasree","year":"2024","journal-title":"Cureus"},{"key":"10.1016\/j.oooo.2026.07.006_bib0033","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1200\/JCO.2016.70.6994","article-title":"Final results of the IELSG-19 randomized trial of mucosa-associated lymphoid tissue lymphoma: improved event-free and progression-free survival with rituximab plus chlorambucil versus either chlorambucil or rituximab monotherapy","volume":"35","author":"Zucca","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.oooo.2026.07.006_bib0034","doi-asserted-by":"crossref","DOI":"10.1186\/s12935-022-02706-8","article-title":"Recent advances and limitations of mTOR inhibitors in the treatment of cancer","volume":"22","author":"Ali","year":"2022","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.oooo.2026.07.006_bib0035","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/cncr.24696","article-title":"Preliminary characterization of oral lesions associated with inhibitors of mammalian target of rapamycin in cancer patients","volume":"116","author":"Sonis","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.oooo.2026.07.006_bib0036","first-page":"1549","article-title":"Stomatitis and EGFR-tyrosine kinase inhibitors: a review of current literature in 4353 patients","volume":"3","author":"Arena","year":"2018","journal-title":"Clin Oncol"},{"key":"10.1016\/j.oooo.2026.07.006_bib0037","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1200\/JCO.2013.50.3961","article-title":"Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma","volume":"32","author":"Hutson","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.oooo.2026.07.006_bib0038","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.oraloncology.2011.08.009","article-title":"Clinical presentation and management of mTOR inhibitor-associated stomatitis","volume":"47","author":"De Oliveira","year":"2011","journal-title":"Oral Oncol"},{"key":"10.1016\/j.oooo.2026.07.006_bib0039","article-title":"Emerging targeted therapies in oral oncology: focus on EGFR inhibition","volume":"11","author":"Veeraraghavan","year":"2024","journal-title":"Oral Oncol Rep"},{"key":"10.1016\/j.oooo.2026.07.006_bib0040","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/5035217","article-title":"Stomatitis and VEGFR-tyrosine kinase inhibitors (VR-TKIs): a review of current literature in 4369 patients","volume":"2018","author":"Arena","year":"2018","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.oooo.2026.07.006_bib0041","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1634\/theoncologist.2010-0263","article-title":"Sunitinib in metastatic renal cell carcinoma: recommendations for management of noncardiovascular toxicities","volume":"16","author":"Kollmannsberger","year":"2011","journal-title":"Oncologist"},{"key":"10.1016\/j.oooo.2026.07.006_bib0042","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1007\/s10637-011-9763-9","article-title":"Nilotinib in patients with metastatic melanoma harboring KIT gene aberration","volume":"30","author":"Cho","year":"2012","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.oooo.2026.07.006_bib0043","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.ejon.2011.05.001","article-title":"Strategies for assessing and managing the adverse events of sorafenib and other targeted therapies in the treatment of renal cell and hepatocellular carcinoma: recommendations from a European nursing task group","volume":"16","author":"Edmonds","year":"2012","journal-title":"Eur J Oncol Nurs"},{"key":"10.1016\/j.oooo.2026.07.006_bib0044","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1200\/JCO.2008.21.6994","article-title":"Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma","volume":"28","author":"Hutson","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.oooo.2026.07.006_bib0045","article-title":"Oral adverse events associated with BRAF and MEK inhibitors in melanoma treatment: a narrative literature review","volume":"12","author":"Basilicata","year":"2024","journal-title":"Healthcare (Switzerland)"},{"key":"10.1016\/j.oooo.2026.07.006_bib0046","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.oraloncology.2015.09.003","article-title":"Oral adverse events in cancer patients treated with VEGFR-directed multitargeted tyrosine kinase inhibitors","volume":"51","author":"Yuan","year":"2015","journal-title":"Oral Oncol"},{"key":"10.1016\/j.oooo.2026.07.006_bib0047","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.oooo.2026.07.006_bib0048","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/S1470-2045(15)00290-9","article-title":"Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial","volume":"16","author":"Motzer","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.oooo.2026.07.006_bib0049","article-title":"Clinical development and management of adverse events associated with FGFR inhibitors","volume":"4","author":"Subbiah","year":"2023","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.oooo.2026.07.006_bib0050","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.907377","article-title":"Safety and efficacy of the pan-FGFR inhibitor erdafitinib in advanced urothelial carcinoma and other solid tumors: a systematic review and meta-analysis","volume":"12","author":"Zheng","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.oooo.2026.07.006_bib0051","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/S1470-2045(14)70472-3","article-title":"Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial","volume":"15","author":"Ellis","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.oooo.2026.07.006_bib0052","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1158\/2159-8290.CD-20-1598","article-title":"Activity and safety of mobocertinib (Tak-788) in previously treated non\u2013small cell lung cancer with egfr exon 20 insertion mutations from a phase I\/II trial","volume":"11","author":"Riely","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.oooo.2026.07.006_bib0053","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1634\/theoncologist.2011-0198","article-title":"Characteristics of oral mucosal events related to bevacizumab treatment","volume":"17","author":"Gavrilovic","year":"2012","journal-title":"Oncologist"},{"key":"10.1016\/j.oooo.2026.07.006_bib0054","doi-asserted-by":"crossref","first-page":"411","DOI":"10.5114\/aoms.2020.99899","article-title":"Clinical efficacy and safety of rituximab with membranous nephropathy: a meta-analysis","volume":"19","author":"Zhong","year":"2023","journal-title":"Arch Med Sci"},{"issue":"2","key":"10.1016\/j.oooo.2026.07.006_bib0055","first-page":"107","article-title":"Taste bud regeneration and the search for taste progenitor cells","volume":"148","author":"Miura","year":"2010","journal-title":"Arch Ital Biol"},{"key":"10.1016\/j.oooo.2026.07.006_bib0056","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.lungcan.2015.01.018","article-title":"Successful treatment of crizotinib-induced dysgeusia by switching to alectinib in ALK-positive non-small cell lung cancer","volume":"88","author":"Koizumi","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.oooo.2026.07.006_bib0057","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.ejcsup.2013.07.016","article-title":"Understanding and managing toxicities of vascular endothelial growth factor (VEGF) inhibitors","volume":"11","author":"Schmidinger","year":"2013","journal-title":"Eur J Cancer Suppl"},{"key":"10.1016\/j.oooo.2026.07.006_bib0058","doi-asserted-by":"crossref","DOI":"10.3390\/molecules27165295","article-title":"Overview of research into mTOR inhibitors","volume":"27","author":"Mao","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.oooo.2026.07.006_bib0059","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1009290","article-title":"Everolimus for advanced pancreatic neuroendocrine tumors","volume":"364","author":"Yao","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.oooo.2026.07.006_bib0060","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1109653","article-title":"Everolimus in postmenopausal hormone-receptor\u2013positive advanced breast cancer","volume":"366","author":"Baselga","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.oooo.2026.07.006_bib0061","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa1915315","article-title":"Rituximab for high-risk, mature B-cell non-Hodgkin\u2019s lymphoma in children","volume":"382","author":"Minard-Colin","year":"2020","journal-title":"N Engl J Med"}],"container-title":["Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212440326003809?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212440326003809?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T12:36:35Z","timestamp":1792067795000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212440326003809"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":61,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["S2212440326003809"],"URL":"https:\/\/doi.org\/10.1016\/j.oooo.2026.07.006","relation":{},"ISSN":["2212-4403"],"issn-type":[{"value":"2212-4403","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oral toxicities secondary to targeted therapies in patients with cancer: a large retrospective analysis","name":"articletitle","label":"Article Title"},{"value":"Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.oooo.2026.07.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}